Navigation Links
Volcano Corporation Schedules First Quarter Conference Call, Webcast
Date:4/22/2013

SAN DIEGO, April 22, 2013 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will report its operating results for the first quarter of fiscal 2013 on Thursday, May 2.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), Thursday, May 2, hosted by Scott Huennekens , president and chief executive officer, and John Dahldorf , chief financial officer.

The teleconference can be accessed by calling (631) 291-4555, passcode 34024703. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available through the company's website at www.volcanocorp.com.

A replay of the conference call will be available through Thursday, May 9, at (404) 537-3406, passcode 34024703, and via the company's website.

About Volcano Corporation

Volcano Corporation (Nasdaq: VOLC) is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information—using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more informa
'/>"/>

SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015  Eli Lilly and Company (NYSE: ... announced that they have entered into a clinical trial ... AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination ... antiangiogenic cancer medicine. The planned study will assess the ... tumors. The Phase I study is expected ...
(Date:5/29/2015)... prostate surgeon and New York Urologist, Dr. David Samadi ... Fusion-Guided Biopsy for detecting aggressive prostate cancer . ... Lenox Hill Hospital is the only center using the revolutionary ... City . We,ve seen tremendous improvement in detecting and ... an MRI makes for a much more accurate diagnosis, especially ...
(Date:5/28/2015)...  Eli Lilly and Company (NYSE: LLY ) announced ... offer for up to $1.6 billion aggregate principal amount of ... notes who tendered, and did not validly withdraw, their notes ... time, on May 27, 2015 (the early tender ... eligible to receive the total consideration. The total consideration for ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
(Date:5/29/2015)... 29, 2015 Ready to hit the road? ... all drivers to get their vehicles ready. With handicapped vehicles, ... Advanced Driving Systems (ADS) is ready to help drivers get ... for summer road trips. , When planning for the big ... ensure that the trip goes smoothly and they are prepared ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 John A. ... to Cincinnati , The Department of Veterans Affairs (VA) ... Gennaro as the new director of the Cincinnati VA ... care to more than 43,000 unique Veterans annually and ... over 2,000 staff, CVAMC is a two-division campus located ...
(Date:5/29/2015)... May 29, 2015 According to a recent ... 10 full-time workers has a substance abuse problem - the ... than 111,500 adults with full-time jobs, revealed that 9.5% of ... previous year. (1) The National Council on Alcoholism and Drug ... year, and an estimated 70% of the 14.8 million illicit ...
(Date:5/29/2015)... Johnson & Johnson and its ... lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with a California ... use of the antipsychotic medication. According to court ... third bellwether trial to involve male breast growth ... Pennsylvania’s Philadelphia Court of Common Pleas, where more ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Inspire Nexus, ... created a solution to the question many life coaches ... gain the experience and hours necessary to become a ... pondered this question, but not for long. Inspire Nexus, ... to hire Coaches directly. Coaches who have experience coaching ...
Breaking Medicine News(10 mins):Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 3Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3
... Jan. 12 Just because you are traveling or,on holiday ... good health habits.,In fact, it is an easier time to ... ) , Many Americans take to ... -- be it business or pleasure, and they often fall ...
... developers summit for companies interested in integrating NurseTesting ... ... (Vocus) January 12, 2009 -- Analysts and industry-watchers believe ... but also the entire nature of the business models that ...
... Medical Equipment the 17th fastest growing business in Louisville, Business First ... , ... (Vocus) January 12, 2009 -- DRE, Inc., a premier international ... of Louisville as a 2008 Company of the Year. The award caps ...
... open enrollment helps Medicare recipients make sure they,ve made the ... ... (Vocus) January 12, 2009 -- Although annual Medicare enrollment has ... during the current Medicare open enrollment period. That information comes ...
... Sweden The Swedish investment,company Karolinska Development AB has ... stem cell and other tissue engineering based,treatments for veterinary ... 2007 EvoStem Finland Oy introduced its first product TendoStem(R),which ... and ligament injuries,in horses. TendoStem(R) is currently on the ...
... Inc., a drug development company focusing on serious Central ... that it held an initial closing of $2.9 million ... will use the funds for the clinical development of ... slowing down disease progression and improving memory and cognition ...
Cached Medicine News:Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Traveling is a Time to be Even Healthier 2Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Traveling is a Time to be Even Healthier 3Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Traveling is a Time to be Even Healthier 4Health News:NurseTesting 2.0 Goes to the Clouds and Invites Developers to Summit 2Health News:NurseTesting 2.0 Goes to the Clouds and Invites Developers to Summit 3Health News:Business First Selects DRE Medical Equipment as a Company of the Year 2Health News:Business First Selects DRE Medical Equipment as a Company of the Year 3Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 2Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 3Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 4Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 5Health News:Karolinska Development Invests in EvoStem Finland Oy 2Health News:New Venture Funding for Alzheimer's Disease Drug Developer 2
Test for determination of rheumatoid factor....
... The SYNCHRON CX4 Delta Specialty / ... access analyzer that can consolidate Drugs ... testing, such as thyroid, HbA1c and ... CX4 Delta offers a level of ...
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
Medicine Products: